Publication
Article
Participating Faculty
Managed Care Pharmacy and the Evolving Diabetes Treatment Paradigm-Are We Capable of Disease Control?
This supplement to The American Journal of Managed Care reviews the efficacy and safety of incretin-based therapies in type 2 diabetes, discusses barriers to effective management of this disease, and describes strategies and interventions that can be implemented by managed care to ensure optimal outcomes.
Faculty
Jeffrey D. Dunn, PharmD, MBA
Formulary and Contract Manager
SelectHealth, Inc.
Alan J. Garber, MD, PhD, FACE
Professor of Medicine, Biochemistry and Molecular Biology,
and Molecular & Cellular Biology
Division of Diabetes, Endocrinology, & Metabolism
Baylor College of Medicine
Curtis Triplitt, PharmD, CDE
Clinical Assistant Professor of Medicine
Texas Diabetes Institute
Clinical Assistant Professor of Pharmacy
University of Texas Health Science Center at San Antonio
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a posi­tion to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommenda­tions. PIM is committed to providing its learners with high-quality CME activi­ties and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.
Faculty Disclosures
Within the past 12 months, the faculty reported the following financial relation­ships or relationships to products or devices they or their spouse/life partner have had with commercial interests related to the content of this CME activity:
Jeffrey D. Dunn, PharmD, MBA
Consultant/advisory boards: AstraZeneca, Takeda, United BioSource
Receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk
Alan J. Garber, MD, PhD, FACE
Consultant/advisory boards/grants/honoraria/lecturer/meeting or conference attendance: Merck, Novo Nordisk
Expert testimony/receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk
Curtis Triplitt, PharmD, CDE
Lecturer/receipt of payment for involvement in the preparation of this manuscript: Novo Nordisk
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have had with commercial interests related to the content of this CME activity:
Steve Casebeer, MBA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Patricia Staples, MSN, NP-C, CCR-N; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD
; and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner have not had any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The American Journal of Managed Care has no relevant financial relationships to disclose.
